Erin T. Aslakson

Stifel Nicolaus analysts John W. Guinee and Erin T. Aslakson upgraded their rating of BioMed Realty Trust, Inc. (NYSE: BMR) from a Hold to a Buy with a price target of $16 on Friday. The Stifel Nicolaus analysts upgraded BioMed Realty Trust price relative to earnings are below those of the REIT...